Up next

DCAT Value Chain Insights Bonus Coverage: From DCAT Week 2024: Supplier News Roundup 

What other DCAT Member Companies are making the news? A roundup of the latest developments from CDMOs/CMOs and other suppliers in drug-substance (small molecules & biologics) and drug-product development and manufacturing and packaging.

What other DCAT Member Companies are making the news? A roundup of the latest developments from CDMOs/CMOs and other suppliers in drug-substance (small molecules & biologics) and drug-product development and manufacturing and packaging. 

Companies making the news 
Here is a roundup of recent news announcements from DCAT Member Companies across the bio/pharmaceutical manufacturing value chain: from active pharmaceutical ingredients (small molecules and biologics) to drug products (solid dosage, injectables and specialty dosage forms), and packaging.  
 
See related stories and the companies making the news below:   

From DCAT Week 2024: Supplier News: Chemicals/Chemical API Manufacturing
Featuring news from Olon, Grace, PharmaBlock, Axplora, ChemCon, Suven Pharma and The Solubility Company. 

From DCAT Week 2024: Supplier News: Biologics Manufacturing
Featuring news from Siegfried and Solvias. 

From DCAT Week 2024: Supplier News: Formulation Development/Drug Product Manufacturing 
Featuring news from Alcami, Corealis Pharma, Curia, Delpharm and Grand River Aseptic Manufacturing. 

From DCAT Week 2024: Supplier News: End-to-End (Drug Substance and Drug Product)
Featuring news from Lonza and Mabion.  

From DCAT Week 2024: Supplier News: Packaging 
Featuring news from Adare Pharma Solutions and ApiJect 

Recent Feature Articles

FDA Begins Pilot To Incentivize US-Based Pharma Manufacturing

By
FDA has selected seven companies to participate in the agency’s PreCheck Pilot Program, a new initiative designed to incentivize US-based pharma manufacturing and facilitate operational readiness of greenfield facilities. Which companies were selected, and what does the program entail?

Mid-Year Review: What’s Trending in New Drug Approvals?

By
FDA’s Center for Drug Evaluation and Research has approved 24 new drugs thus far in 2026. Which companies and drug candidates have crossed the finish line, and how is the product mix between small molecules and biologics faring?

New CEO Takes the Helm of Takeda: What’s Next?

By
In a planned succession, Julie Kim took the helm at Takeda as President and CEO with former President and CEO Christophe Weber stepping down following a 12-year tenure. The company faces a transitional period as it seeks to return to growth. What’s the plan?
Wave

The State of the State: Continuous Manufacturing

By
FDA’s Emerging Technology Program, a collaborative program between the agency and industry, aims to facilitate bio/pharma companies’ adoption of new manufacturing technologies, including continuous manufacturing. Where do things stand?